One Amgen Center Drive
We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.
We live the mission.
We win together.
We thrive on continual challenge.
Our team of 22,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.
At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.
Connect with us to explore how you can Win, Live, and Thrive at Amgen.
2434 articles about Amgen
NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia® (denosumab) injection reduced fracture risk in patients versus oral alendronate, a frequently prescribed bisphosphonate treatment.
Amgen to Present at the 2023 Bank of America Merrill Lynch Global Healthcare Conference
Amgen will present at the 2023 Bank of America Merrill Lynch Global Healthcare Conference at 11:00 a.m. ET on Tuesday, May 9, 2023.
In the past few weeks, the biopharma industry has been filled with layoffs and company launches. To learn about job opportunities at some of the industry's top companies, see inside.
Amgen Reports First Quarter 2023 Financial Results
Amgen announced financial results for the first quarter of 2023.
AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S. financial markets.
Lilly investigators said they hoped to differentiate their Phase I candidate from the competitive KRAS space by making it the first to gain approval as a first-line treatment.
Amgen and NSG Biolabs Announce Albatroz Therapeutics as Winner of First Amgen Golden Ticket in Singapore
Leading global biotechnology company Amgen and NSG BioLabs, Singapore's largest and leading provider of biotechnology co-working laboratories and offices, announced Albatroz Therapeutics as the winner of the first Amgen Golden Ticket in Singapore.
Amgen is terminating 450 workers in hopes of weathering dropping drug prices and rising inflation. This is Amgen's second round of job cuts this year.
Amgen to Present at the 33rd Annual Oppenheimer Healthcare Conference
Amgen will present at the 2023 Oppenheimer Healthcare Conference at 2:00 p.m. ET on Monday, March 13, 2023.
AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the second quarter of 2023.
Amgen to Present at the 43rd Annual TD Cowen Healthcare Conference
Amgen will present at the 2023 TD Cowen Healthcare Conference at 11:10 a.m. ET on Wednesday, March 8, 2023.
AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC
Amgen (NASDAQ: AMGN) today announced new Repatha® (evolocumab) combined data from the Phase 3 FOURIER and FOURIER Open Label Extension (OLE) studies and the Phase 2 OCEAN(a)-DOSE study of investigational olpasiran, an siRNA that reduces lipoprotein(a) [Lp(a)] by more than 90%.
AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS
Amgen (NASDAQ:AMGN) today announced the African American Heart Study, in collaboration with the Association of Black Cardiologists (ABC) and the Morehouse School of Medicine (MSM), which will measure the association between Lipoprotein(a), or Lp(a), and atherosclerotic cardiovascular disease (ASCVD) in 5,000 African American individuals across the United States
AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE
Amgen (NASDAQ:AMGN) will present at the 2023 SVB Securities Global Biopharma Conference at 10:40 a.m. ET on Tuesday, February 14, 2023.
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.
TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN
Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.
Amgen Posts Full Transcript and Audio Replay of Fourth Quarter and Full Year 2022 Earnings Webcast
Amgen posted the full transcript and audio replay of the company's 2022 fourth quarter and full year financial results webcast from earlier.
AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira ®* (adalimumab), is now available in the United States.
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021.
Amgen is implementing organizational changes including laying off approximately 300 team members, confirmed Monday.